These data confirm the potential of combined therapy with resveratrol and rapamycin to inhibit bladder cancer cell growth and induce cancer cell death, which could be specifically fitted for bladder cancer patients with tumors characterized by TSC1 mutations or activating PI3K/mTORC1 pathway mutations. Here, TSC1 is linked to urinary bladder carcinoma.